查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403526

肝病診斷市場至2030年的預測：按疾病類型、技術、最終用戶和地區的全球分析

Liver Disease Diagnostics Market Forecasts to 2030 - Global Analysis By Disease Type (Viral Hepatitis, Alcoholic Liver Disease, Non-alcoholic Fatty Liver Disease, Liver Cancer and Other Disease Types), Technique, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球肝病診斷市場規模為 403.2 億美元，預計預測期內年複合成長率為 8.1%，到2030年將達到 695.4 億美元。

肝病診斷劑對於各種肝臟相關疾病的診斷和治療非常重要。這些診斷包括目的是評估肝臟健康，識別異常並確定肝臟疾病的根本原因的各種程序和影像方式。此外，測量肝酵素值 （例如丙氨酸轉氨酶（ALT）和天冬氨酸轉氨酶（AST））的血液檢查以及評估某些抗體或病毒標記物是否存在的測試也是常用的診斷工具。

根據世界衛生組織（WHO）2022年6月發布的報告，全球整體估計有5,800萬人感染慢性C型肝炎病毒，每年新增感染者約150萬人。

提高認知和篩檢工作

隨著非營利組織和醫療保健組織宣傳活動提高了公眾對肝病嚴重性的認知，肝病診斷的需求量很大。此外，由於針對高風險族群（例如有吸毒史的人群或具有某些易患肝病的人口特徵的人群）的積極篩檢計劃，早期診斷日益增加。除了減輕醫療保健系統的負擔之外，對預防醫學的關注和認知的提高也使人們有能力透過定期檢查來管理肝臟健康。

先進診斷的成本過高

主要障礙是尖端肝病診斷的成本，包括先進的影像方式和分子測試。總成本由高昂的初始投資、持續的維護成本以及專業培訓的需求決定。此外，這些經濟障礙阻礙了這些診斷技術的廣泛使用以及患者和醫療機構等的使用。

個體化醫療的發展

由於個人化醫療的變化，肝病診斷市場存在重大機會。透過根據患者的基因組成，生活方式選擇和疾病特異性特徵來客製化診斷策略，可以使肝病的診斷和治療更加準確。此外，基因組學和分子分析的進步使得有針對性的診斷工具的創建成為可能，為更有效率和客製化的患者照護打開了大門。

合規和監管問題

肝病診斷市場正面臨著更嚴格和動態的法規環境的威脅。公司面臨時間和資源方面的挑戰，因為他們必須遵守合規性要求、獲得必要的核准並應對複雜的監管流程，這也可能會延遲產品發布。然而，對於市場參與企業而言，違規會帶來嚴重風險，包括法律問題、市場退出和監管後果。

COVID-19 的影響：

肝病診斷市場受到了 COVID-19 大流行的嚴重影響。大流行造成的全球破壞包括封鎖，醫療保健系統負擔過重，重新調整資源來對抗病毒，暫時減少選擇性手術和例行就診的數量，以及減少整體診斷服務的需求。此外，由於研發計劃的延誤，供應鏈中斷和醫療保健優先事項的轉變，市場參與企業面臨挑戰。此次疫情凸顯了強大診斷能力的重要性，加速了遠端醫療和遠端監控解決方案的採用。

非酒精性脂肪肝（NAFLD）預計將成為預測期內最大的區隔

非酒精性脂肪肝疾病（NAFLD）預計將佔據最大佔有率。隨著肥胖和代謝症候群變得越來越普遍，非酒精性脂肪肝（NAFLD）已成為世界上慢性肝病的主要原因。此外，NAFLD（從輕度肝脂肪變性到非酒精性脂肪性肝炎（NASH）等嚴重）盛行率不斷上升，推動這一領域的主導地位。因此，對肝病診斷的需求顯著增加，包括使用最先進的影像方式和血液檢測來準確診斷和分期 NAFLD。

研究機構部門預計在預測期內年複合成長率最高

預測期內年複合成長率最高的領域是研究機構。研究機構對於促進診斷設備和程序開發的創新和技術進步非常重要。該領域的強勁成長得益於對轉化研究、生物標記發現和創新診斷技術開發的日益關注。此外，研究機構還與診斷公司和醫療保健提供者合作進行臨床研究、檢驗診斷測定並主導新型​​診斷技術的開發。政府津貼和資助推動研究機構產業不斷發展，研究活動活性化。

佔有率最大的地區

預計北美將佔據最大的市場佔有率。鼓勵創新的強力的法規環境，高額醫療保健支出，技術進步和完善的醫療保健基礎設施是該地區佔據主導地位的部分原因。此外，由於存在重要的市場參與者和研究機構，以及積極實施先進診斷技術，北美在肝病診斷市場佔據主導地位。

年複合成長率最高的地區：

醫療診斷市場預計將以亞太地區最高的年複合成長率成長。這是由於該地區人口不斷成長，慢性病發病率不斷上升，公眾對早期疾病檢測的意識不斷增強，以及對醫療基礎設施的大量投資。快速成長主要歸功於中階的不斷壯大，政府為改善醫療保健服務所做的努力，以及中國等國家和醫療保健領域的技術進步。此外，由於亞太地區的動態性和對實施尖端診斷解決方案的專注，亞太地區在醫療保健診斷行業的強勁成長中處於有利地位。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球肝病診斷市場：依疾病類型

  • 病毒性肝炎
  • 酒精性肝臟疾病
  • 非酒精性脂肪肝（NAFLD）
  • 肝癌
  • 其他類型的疾病

第6章 全球肝病診斷市場：依技術分類

  • 內視鏡檢查
  • 切片檢查
  • 成像技術
    • 超音波
    • MRI
    • 電腦斷層掃描
  • 臨床檢查
    • 驗血
    • 肝功能檢查
    • 基因檢測
  • 其他技術

第7章 全球肝病診斷市場：依最終使用者分類

  • 醫院
  • 實驗室
  • 研究機構
  • 其他最終用戶

第8章 全球肝病診斷市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Abbott Laboratories
  • Horiba Medical
  • F. Hoffmann-La Roche Ltd.
  • Cosara Diagnostics Pvt Ltd
  • Laboratory Corporation of America Holdings
  • Bio-Rad Laboratories Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Fujifilm Corporation
  • PerkinElmer
  • Biosino Bio-Technology and Science Inc
  • Quest Diagnostics Incorporated
  • Trivitron Healthcare
  • Boston Scientific Corporation
  • Qiagen NV
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc
  • Randox Laboratories Ltd.
Product Code: SMRC24751

According to Stratistics MRC, the Global Liver Disease Diagnostics Market is accounted for $40.32 billion in 2023 and is expected to reach $69.54 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Diagnostics for liver diseases are essential for determining and treating a wide range of liver-related conditions. These diagnostics include a variety of procedures and imaging methods designed to evaluate the liver's health, identify anomalies, and identify the underlying causes of liver diseases. Moreover, blood tests to measure liver enzyme levels, such as alanine transaminase (ALT) and aspartate transaminase (AST), as well as tests to assess the presence of particular antibodies or viral markers, are commonly used diagnostic tools.

According to report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.

Market Dynamics:

Driver:

Growing consciousness and screening initiatives

Liver disease diagnostics are in high demand due to growing public awareness of the seriousness of liver diseases, which has been fueled by campaigns from non-profits and healthcare groups. Additionally, early-stage diagnoses are increasing as a result of proactive screening programs, which typically target high-risk populations such as those with a history of substance abuse or particular demographics predisposed to liver disorders. In addition to lessening the strain on healthcare systems, this increased focus and awareness of preventive healthcare also give people the power to take control of their liver health through routine screenings.

Restraint:

Exorbitant expense of advanced diagnosis

A major barrier is the expense of cutting-edge liver disease diagnostics, which include sophisticated imaging methods and molecular testing. The total cost is influenced by a high initial investment, ongoing maintenance expenses, and the requirement for specialized training. Furthermore, this financial obstacle prevents these diagnostics from being widely used and made accessible to patients and healthcare organizations alike.

Opportunity:

Developments in customized medicine

There is a large opportunity for the liver disease diagnostics market due to the changing face of personalized medicine. Liver disease diagnosis and treatment can be made more accurate by customizing diagnostic strategies based on a person's genetic composition, lifestyle choices, and unique disease features. Moreover, the creation of targeted diagnostic tools is made possible by developments in genomics and molecular profiling, which open the door to more efficient and customized patient care.

Threat:

Issues with compliance and regulatory difficulties

The market for liver disease diagnostics is threatened by stricter and more dynamic regulatory environments. Companies face difficulties in terms of time, resources, and possible delays in product launches when they must follow compliance requirements, secure required approvals, and navigate complex regulatory processes. However, for market participants, non-compliance poses a serious risk of legal problems, market withdrawals, or restrictions.

COVID-19 Impact:

The market for liver disease diagnostics has been significantly impacted by the COVID-19 pandemic. The pandemic's worldwide disruption, which included lockdowns, overburdened healthcare systems, and the redirection of resources to fight the virus, temporarily, reduced the number of elective surgeries and routine medical visits, which had an impact on the demand for diagnostic services as a whole. Additionally, market participants faced difficulties due to delays in R&D projects, interruptions in the supply chain, and changes in healthcare priorities. Positively, the pandemic accelerated the adoption of tele-health and remote monitoring solutions by highlighting the significance of strong diagnostic capabilities.

The Non-alcoholic Fatty Liver Disease (NAFLD) segment is expected to be the largest during the forecast period

The non-alcoholic fatty liver disease (NAFLD) segment is anticipated to hold the largest share. Since obesity and metabolic syndrome are becoming more common, non-alcoholic fatty liver disease (NAFLD) has emerged as a major global cause of chronic liver disease. Furthermore, the rising prevalence of NAFLD, which can vary from mild hepatic steatosis to more serious illnesses like non-alcoholic steatohepatitis (NASH), is what drives the segment's dominance. Because of this, there has been a noticeable increase in the need for liver disease diagnostics, such as cutting-edge imaging methods and blood tests for precise NAFLD diagnosis and staging.

The Research Institutes segment is expected to have the highest CAGR during the forecast period

The segment with the highest CAGR during the estimation period is research institutes. Research institutes are essential for fostering innovation and technical progress in the development of diagnostic instruments and procedures. The robust growth of this segment can be attributed to the growing emphasis on translational research, biomarker discovery, and the development of innovative diagnostic technologies. Moreover, research institutes conduct clinical studies, validate diagnostic assays, and lead the way in developing novel diagnostic techniques in partnership with diagnostic companies and healthcare providers. Government grants and funding, along with the increased volume of research activity, are driving the Research Institutes sector forward.

Region with largest share:

North America is expected to hold the largest market share. A strong regulatory environment that encourages innovation, high healthcare spending, technological advancements, and a well-established healthcare infrastructure are some of the reasons for the region's dominance. Additionally, North America holds a dominant position in the liver disease diagnostics market due in part to the existence of important market players, research institutions, and a proactive approach towards adopting advanced diagnostic technologies.

Region with highest CAGR:

The healthcare diagnostics market is expected to grow at the highest CAGR in the Asia-Pacific region. The region's expanding population, the rising frequency of chronic diseases, the increased public awareness of early disease detection, and the significant investments made in healthcare infrastructure are all contributing factors to this. The rapid growth is mostly being driven by middle-class population expansion, government initiatives to increase healthcare accessibility, and technological advancements in countries like China and India. Furthermore, the Asia-Pacific region is well-positioned for strong growth in the healthcare diagnostics industry due to its dynamic nature and emphasis on implementing cutting-edge diagnostic solutions.

Key players in the market:

Some of the key players in Liver Disease Diagnostics market include Abbott Laboratories, Horiba Medical, F. Hoffmann-La Roche Ltd., Cosara Diagnostics Pvt Ltd, Laboratory Corporation of America Holdings, Bio-Rad Laboratories Inc., Meril Life Sciences Pvt. Ltd., Fujifilm Corporation, PerkinElmer, Biosino Bio-Technology and Science Inc, Quest Diagnostics Incorporated, Trivitron Healthcare, Boston Scientific Corporation, Qiagen N.V, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc and Randox Laboratories Ltd.

Key Developments:

In December 2023, F. Hoffmann-La Roche Ltd. announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In August 2022, HORIBA, one of the global leaders in a wide range of medical diagnostic equipment, and SigTuple, a medtech company that develops AI-powered digital microscopy solutions, announced today a partnership to accelerate adoption of SigTuple's AI100 across the Indian subcontinent. HORIBA, a medical diagnostic company, and SigTuple, a MedTech company, on Monday, announced a partnership to accelerate the adoption of SigTuple's AI100 across the Indian subcontinent.

Disease Types Covered:

  • Viral Hepatitis
  • Alcoholic Liver Disease
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Liver Cancer
  • Other Disease Types

Techniques Covered:

  • Endoscopy
  • Biopsy
  • Imaging Techniques
  • Laboratory Tests
  • Other Techniques

End Users Covered:

  • Hospitals
  • Laboratories
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liver Disease Diagnostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Viral Hepatitis
  • 5.3 Alcoholic Liver Disease
  • 5.4 Non-alcoholic Fatty Liver Disease (NAFLD)
  • 5.5 Liver Cancer
  • 5.6 Other Disease Types

6 Global Liver Disease Diagnostics Market, By Technique

  • 6.1 Introduction
  • 6.2 Endoscopy
  • 6.3 Biopsy
  • 6.4 Imaging Techniques
    • 6.4.1 Ultrasound
    • 6.4.2 MRI
    • 6.4.3 CT Scan
  • 6.5 Laboratory Tests
    • 6.5.1 Blood Tests
    • 6.5.2 Liver Function Tests
    • 6.5.3 Genetic Tests
  • 6.6 Other Techniques

7 Global Liver Disease Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Laboratories
  • 7.4 Research Institutes
  • 7.5 Other End Users

8 Global Liver Disease Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Horiba Medical
  • 10.3 F. Hoffmann-La Roche Ltd.
  • 10.4 Cosara Diagnostics Pvt Ltd
  • 10.5 Laboratory Corporation of America Holdings
  • 10.6 Bio-Rad Laboratories Inc.
  • 10.7 Meril Life Sciences Pvt. Ltd.
  • 10.8 Fujifilm Corporation
  • 10.9 PerkinElmer
  • 10.10 Biosino Bio-Technology and Science Inc
  • 10.11 Quest Diagnostics Incorporated
  • 10.12 Trivitron Healthcare
  • 10.13 Boston Scientific Corporation
  • 10.14 Qiagen N.V
  • 10.15 Siemens Healthcare GmbH
  • 10.16 Thermo Fisher Scientific Inc
  • 10.17 Randox Laboratories Ltd.

List of Tables

  • Table 1 Global Liver Disease Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 4 Global Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 5 Global Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 6 Global Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 7 Global Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 8 Global Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 9 Global Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 10 Global Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 11 Global Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 12 Global Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 13 Global Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 14 Global Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 15 Global Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 16 Global Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 17 Global Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 18 Global Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 19 Global Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 20 Global Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 23 Global Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 24 Global Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 27 North America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 28 North America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 29 North America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 30 North America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 31 North America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 32 North America Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 33 North America Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 34 North America Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 35 North America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 36 North America Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 37 North America Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 38 North America Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 39 North America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 40 North America Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 41 North America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 42 North America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 43 North America Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 44 North America Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 North America Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 47 North America Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 48 North America Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 51 Europe Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 52 Europe Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 53 Europe Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 54 Europe Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 55 Europe Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 56 Europe Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 57 Europe Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 58 Europe Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 59 Europe Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 60 Europe Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 61 Europe Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 62 Europe Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 63 Europe Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 64 Europe Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 65 Europe Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 66 Europe Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 67 Europe Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 68 Europe Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 69 Europe Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 70 Europe Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 71 Europe Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 72 Europe Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 75 Asia Pacific Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 76 Asia Pacific Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 77 Asia Pacific Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 78 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 79 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 80 Asia Pacific Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 81 Asia Pacific Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 82 Asia Pacific Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 83 Asia Pacific Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 84 Asia Pacific Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 85 Asia Pacific Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 86 Asia Pacific Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 87 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 88 Asia Pacific Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 89 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 90 Asia Pacific Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 91 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 92 Asia Pacific Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 93 Asia Pacific Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 94 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 95 Asia Pacific Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 96 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 99 South America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 100 South America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 101 South America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 102 South America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 103 South America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 104 South America Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 105 South America Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 106 South America Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 107 South America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 108 South America Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 109 South America Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 110 South America Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 111 South America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 112 South America Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 113 South America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 114 South America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 115 South America Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 116 South America Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 South America Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 118 South America Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 119 South America Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 120 South America Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 123 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 124 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 125 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 126 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 127 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 128 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 129 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 130 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 131 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 132 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 133 Middle East & Africa Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 134 Middle East & Africa Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 135 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 136 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 137 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 138 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 139 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 140 Middle East & Africa Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 141 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 142 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 143 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 144 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)